Tau-PNU Medical is developing the trans-catheter to heal MR (Mitral Valve Regurgitation) occurring between the left ventricle and artrium. This kind of trans-cathether is rare and has high level of valuation. During 3 years, 4 start-ups in this fields were acquired right after pre-clinical tests by Medtronic, Edwards and Abbot at the price of $500M ~ $700M.

The company already performed the clinical trial of 5 MR patients successfully with the Korean FDA. The company is preparing the clinical trial of 5 MR and atrial fibrillation patients and passed IND, which will be performed until 2019.

A trans-catheter of Tau-PNU also has a strong point to heal MR and TR at the same time, which is under validation of pre-clinical test in Yangsan Busandae Hospital.